pSivida Corp. announced that initial nationwide shipments of Iluvien for diabetic macular edema (DME) are scheduled to begin in the United States on February 23, according to a company news release.
A live webinar launch event designed for eye care professionals is scheduled for March 2, at 8:30 pm EST by pSivida’s licensee, Alimera Sciences. On the webinar, eight retinal specialists and one glaucoma specialist from around the country will share their experiences with Iluvien, including videos of Iluvien injections, and participate in a live question and answer session to share information about Iluvien. Executives from Alimera will also be available to address product distribution and reimbursement questions. The 1-hour webinar will be accessible on line, and those interested in registering for the webinar may do so in advance at www.ILUVIEN.com.
“We are very pleased that shipments of Iluvien will begin next week,” said Paul Ashton, PhD, president and CEO of pSivida. “Iluvien represents an important treatment option for many diabetics who are losing vision due to DME.” pSivida is entitled to 20% of net profits on the sales of Iluvien on a country-by-country, quarter-by-quarter basis.
Iluvien is an injectable, sustained release micro-insert approved in the US to treat DME patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in IOP. Iluvien delivers the steroid flucinolone acetonide in submicrogram levels on a continuous basis for a period of 36 months. It is expected that Iluvien will be reimbursed in the US for its FDA indication. Alimera has set up a reimbursement and patient assistance program to support practices and patients with respect to Iluvien.